- Home
- LNZA vs GNTA Comparison
LNZA vs GNTA Comparison
Compare LNZA & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LNZA | GNTA |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 39.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | LNZA | GNTA |
|---|---|---|
| Price | $14.60 | $1.89 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | 11.9K | ★ 111.6K |
| Earning Date | 11-19-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,876,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $113.27 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.20 | $1.35 |
| 52 Week High | $274.00 | $10.00 |
Technical Indicators
Market Signals| Indicator | LNZA | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 40.49 |
| Support Level | $13.37 | $1.80 |
| Resistance Level | $15.32 | $2.20 |
| Average True Range (ATR) | 1.43 | 0.24 |
| MACD | 0.48 | 0.04 |
| Stochastic Oscillator | 81.15 | 59.77 |
Price Performance
Historical ComparisonAbout LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a carbon management company transforming waste carbon into sustainable fuels, fabrics, packaging, and nutrition. Its goal is to advance a circular economy where carbon is reused rather than wasted, reducing reliance on virgin fossil resources and supporting supply chain resilience. The company operates in North America, Europe, Middle East, Africa (EMEA), Asia, and Australia.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.